PDE4A and chronic obstructive pulmonary disease: This mechanism has been exploited in the clinical use of PDE‐4 inhibitors like roflumilast and apremilast for chronic inflammatory diseases such as chronic obstructive pulmonary disease (COPD) and psoriasis [6, 8].